6712 Stock Overview
Engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Ever Supreme Bio Technology Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$175.00 |
| 52 Week High | NT$215.00 |
| 52 Week Low | NT$166.00 |
| Beta | 0.30 |
| 11 Month Change | -3.31% |
| 3 Month Change | -4.37% |
| 1 Year Change | -0.77% |
| 33 Year Change | -5.54% |
| 5 Year Change | 44.34% |
| Change since IPO | 155.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6712 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -3.6% | -5.3% | -4.2% |
| 1Y | -0.8% | 0.9% | 28.9% |
Return vs Industry: 6712 underperformed the TW Biotechs industry which returned 0.9% over the past year.
Return vs Market: 6712 underperformed the TW Market which returned 28.9% over the past year.
Price Volatility
| 6712 volatility | |
|---|---|
| 6712 Average Weekly Movement | 2.0% |
| Biotechs Industry Average Movement | 4.3% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6712 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6712's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | n/a | www.ever-supreme.com.tw |
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. The company was incorporated in 2016 and is based in Taichung, Taiwan.
Ever Supreme Bio Technology Co., Ltd Fundamentals Summary
| 6712 fundamental statistics | |
|---|---|
| Market cap | NT$14.12b |
| Earnings (TTM) | NT$254.33m |
| Revenue (TTM) | NT$844.86m |
55.5x
P/E Ratio16.7x
P/S RatioIs 6712 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6712 income statement (TTM) | |
|---|---|
| Revenue | NT$844.86m |
| Cost of Revenue | NT$253.38m |
| Gross Profit | NT$591.48m |
| Other Expenses | NT$337.15m |
| Earnings | NT$254.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.15 |
| Gross Margin | 70.01% |
| Net Profit Margin | 30.10% |
| Debt/Equity Ratio | 0% |
How did 6712 perform over the long term?
See historical performance and comparison